PRIMECAP Management Palvella Therapeutics, Inc.

1 PRIMECAP Management Palvella Therapeutics Trades

PRIMECAP Management acquired 195k Palvella Therapeutics shares worth $21.2M. That's 0.01% of their equity portfolio (230th largest holding). The investor owns 1.51% of the outstanding Palvella Therapeutics stock. The stake costed the investor $19.2M, netting the investor a gain of 10% so far.

News about Palvella Therapeutics, Inc. and PRIMECAP Management

Silverarc Capital Management LLC Acquires New Position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)

… fiscal year. Pieris Pharmaceuticals Profile (Free Report) Pieris Pharmaceuticals , Inc, a … discovers and develops anticalin-based drugs . The company deve...

EIN News Pharmaceuticals, over 2 years ago